Navigation Links
NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Date:3/24/2008

IRVINE, Calif., March 24 /PRNewswire-FirstCall/ -- NuRx Pharmaceuticals, Inc. (OTC Bulletin Board: NURX) today announced it has dosed the first patient in a Phase I clinical trial of the first-in-class rexinoid receptor (RXR) agonist NRX4204.

The single-center study, which NuRx expects to complete in the fourth quarter of this year, is designed to evaluate the safety and tolerability of the compound. NRX4204 is the company's first drug candidate in clinical trials.

"Our preclinical data show that NRX4204 is a highly potent and specific, orally bio-available RXR agonist that is effective in models of non-small cell lung cancer and breast cancer," said Harin Padma-Nathan, M.D., NuRx's president and CEO. "We intend to pursue the development of this compound as a treatment for both indications. There are no rexinoid treatments currently approved for these indications."

NuRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation retinoid and rexinoid compounds for application in oncology (treatment, prevention and adjunctive supportive therapy) and other highly prevalent diseases. The company's lead compounds are NRX4204, a highly specific, first-in-class rexinoid agonist that is targeted for development in non-small cell lung carcinoma and breast cancer and a RAR agonist for the treatment of acute leukemia. Based in Irvine, Calif., NuRx has a technology and IP platform that includes a library of nearly 6,000 compounds supported by 230 issued U.S. and international patents and more than 80 additional patents in application. For more information, visit http://www.nurxpharmaceutical.com.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management as well as assumptions made by and information currently available to the Company or its management. The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this news release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the fact that the Company is engaged in early stage research and does not expect to obtain any revenues for several years and other risks as detailed from time to time in the Company's registration statement and reports and filings with the Securities and Exchange Commission. All forward-looking statements, if any, in this news release represent the Company's judgment as of the date of this news release. The Company disclaims, however, any intent or obligation to update forward-looking statements.

CONTACTS: Media

David Schull

(212) 845-4271

david.schull@russopartnersllc.com

Investors

Parag Dave

(917) 322-2585

pdave@otccommunications.com


'/>"/>
SOURCE NuRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... -- Just 18 months after its February 2016 launch, market ... appointment of three new senior people to its rapidly ... and James Wright bring decades of ... Tammy Wynne joins as Director, Value ... has over ten years, experience in global market access ...
(Date:9/1/2017)... , Sept. 1, 2017 Michael ... Solutions, Inc , highlights opportunities for growth in his ... report that Marlin Equity is seeking a buyer for ... annual award-winning 22-year-old healthcare solutions Value Added Reseller and ... "As the healthcare market ...
(Date:9/1/2017)... , Sept. 1, 2017  Bayer will present the latest ... Society for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... include new preclinical and clinical data on Bayer,s marketed portfolio ... pipeline projects. "We ... minds in cancer research at ESMO," said Carsten Brunn ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: a moving compilation of ... value to God. “Letters From Home” is the creation of published author, John Allred, ... Cabinet of Jerry Savelle Ministries International, who has traveled and ministered on four continents. ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg ... life. Although frozen embryos have a slight statistical advantage for live births, frozen ... a wonderful opportunity for women undergoing medical treatment or who are concerned about ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from ... easy to do. Users can select from up to two layers of subject matter ... of a mouse all within Final Cut Pro X. , With ProSlideshow ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      ... things wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find ...
(Date:9/21/2017)... CA (PRWEB) , ... September 21, 2017 , ... ... lunch and learn with Infinity Behavioral Health Services for professionals in the addiction ... a Commercial Payer Audit . , Insurance companies and state and federal ...
Breaking Medicine News(10 mins):